Skip to main content
. 2017 May 8;8(35):58754–58764. doi: 10.18632/oncotarget.17678

Figure 2.

Figure 2

Growth (A) and LCs50 (B) of drug-sensitive and resistant EC cells in DOX-supplemented medium.